AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00128713 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Medium Dose Prophylactic Platelet Transfusions
Description: 2.2 x 10\^11 platelets per m\^2 BSA
Study NCT03679780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Arginine
Description: A substrate that is administered to increase endogenous nitric oxide production. The infusion rate will be 2 µl/min
Study NCT03679780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NG Nitro L Arginine Methyl Ester
Description: L-Name is a NOS inhibitor that is administered to each site to allow for the quantification of NO contribution to vasodilation. The infusion rate will be 2 µl/min
Study NCT03679780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NG Nitro L Arginine Methyl Ester
Description: L-Name is a NOS inhibitor that is administered to each site to allow for the quantification of NO contribution to vasodilation. The infusion rate will be 2 µl/min
Study NCT03679780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Nitroprusside
Description: SNP will be perfused through each site to induce maximal vasodilation. The infusion rate will be 2 µl/min
Study NCT03679780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Nitroprusside
Description: SNP will be perfused through each site to induce maximal vasodilation. The infusion rate will be 2 µl/min
Study NCT03679780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringer's
Description: Lactated Ringer will serve as the control site. The infusion rate will be 2 µl/min
Study NCT02189473 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: external beam radiotherapy (5 x 4 Gy versus 10 x 3 Gy)
Study NCT02189473 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: external beam radiotherapy (5 x 4 Gy versus 10 x 3 Gy)
Study NCT02594839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bone marrow mesenchymal stem cells
Description: Bone marrow will be harvested in healthy donors followed by separation and cultivation of MSCs. Before infusion cells will be suspended in 400 mL saline
Study NCT02594839 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous infusion of 400 mL saline
Study NCT00565968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Study NCT00565968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Study NCT00565968 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Study NCT00565968 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Study NCT00565968 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: western blotting
Study NCT00565968 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study NCT01622699 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Bilirubinometer
Description: If a baby is jaundiced, the ward-nurse will perform a transcutaneous bilirubin measurement. It takes about 5 seconds to perform the measurement at the forehead or sternum of the baby. The device is a validated measurement-tool, which provides us with an estimated serum bilirubin-concentration. This is not an invasive procedure: A light-reflection is used to measure transcutaneous bilirubin.
Study NCT01622699 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: visual assessment of neonatal jaundice
Description: To detect newborns with jaundice (who will possibly meet the criteria for phototherapy) there have been international guidelines formulated by the American Academy of Pediatrics. The standard of care at the neonatal- and maternity ward of our hospital to detect those newborns is visual assessment according to these guidelines.
Study NCT01226446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: Vitamin D on top of the standard treatment
Study NCT04262843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT04262843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT04262843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT04262843 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor
Description: Growth factor therapy
Study NCT04262843 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: Undergo hematopoietic cell transplantation
Study NCT04262843 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo TMLI
Study NCT04262843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Immunosuppressive therapy
Study NCT04262843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Immunosuppressive therapy
Study NCT01782807 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Salpingectomy or Fimbriectomy
Study NCT00128713 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lower Dose Prophylactic Platelet Transfusions
Description: 1.1 x 10\^11 platelets per m\^2 BSA
Study NCT00128713 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Higher Dose Prophylactic Platelet Transfusions
Description: 4.4 \* 10\^11 platelets per m\^2 BSA
Study NCT03493789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Given IV
Study NCT03493789 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: Undergo FDG-PET
Study NCT03493789 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Undergo SBRT
Study NCT02973776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LEO 90100 aerosol foam
Study NCT02973776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 90100 aerosol foam
Study NCT02973776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LEO 90100 aerosol foam
Study NCT00453921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: Dosage dependent on weight
Study NCT00453921 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Memory and Attention Training
Description: Weekly Memory and Attention Training with at home practice.
Study NCT00453921 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo as both treatments
Description: Placebo capsules and Placebo Memory and Attention Training
Study NCT02973776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dermoval®/Dermovate®
Study NCT03438292 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TPGS emulsified berberine
Description: Two capsules of TPGS/Quillaja extract emulsified berberine. Each capsule contains 400 mg berberine. The total amount of berberine throughout is 800 mg.
Study NCT02973776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dermoval®/Dermovate®
Study NCT02973776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dermoval®/Dermovate®
Study NCT02973776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diprosone
Study NCT03438292 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Quillaja extract emulsified berberine
Description: Four capsules of Quillaja extract emulsified berberine. Each capsule contains 200 mg berberine. The total amount of berberine throughout is 800 mg.
Study NCT01150812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8165
Description: Oral suspension, 2 mg/mL and 20 mg/mL, single doses
Study NCT00314951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fidaxomicin
Description: 200 mg oral capsules two times daily (q12h regimen)
Study NCT00314951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: 125 mg capsules q6hr (4 times a day)
Study NCT00314951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo to Fidaxomicin
Description: Matching Placebo to Fidaxomicin administered two times daily (intermittently with fidaxomicin dosing)
Study NCT04428450 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deprexis
Description: CBT-based, integrative online self-help program
Study NCT02928445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVT-101 35 mg
Description: once daily, oral, 35-mg tablets
Study NCT02928445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVT-101 70 mg
Description: once daily, oral, 35-mg tablets
Study NCT03403647 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Oral daily vitamin D
Study NCT02885766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-114
Study NCT01940991 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, Dose B; dose applied to the lateral canthal lines
Study NCT01940991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Description: Botulinum Toxin Type A, Dose A, dose applied to the lateral canthal lines
Study NCT02973776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diprosone
Study NCT02973776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diprosone
Study NCT02973776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elocon
Study NCT02973776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elocon
Study NCT02973776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Elocon
Study NCT02973776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Locoid
Study NCT03267511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP
Description: Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP and brush twice daily (morning and evening) for one timed minute (in their usual manner).
Study NCT03267511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica
Description: Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica and brush twice daily (morning and evening) for one timed minute (in their usual manner).
Study NCT02973776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Locoid
Study NCT02973776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Locoid
Study NCT02973776 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LEO 90100 foam vehicle
Study NCT02973776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LEO 90100 foam vehicle
Study NCT02973776 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: LEO 90100 foam vehicle
Study NCT03267511 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP
Description: Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP and brush twice daily (morning and evening) for one timed minute (in their usual manner).
Study NCT00928733 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Gastroduodenoscopy- Intraduodenal intubation
Description: 20 g ethanol diluted up to 10% in tap water
Study NCT01616979 — intervention group
Intervention type: PROCEDURE
Intervention: placing saline bag during cardiac displacement
Description: For grafting to LCX territory, the heart is displaced using positioner and a suction-type epicardial stabiliser is applied to the target area. The degree of cardiac displacement and the LV compression by stabilisers are adjusted for maximal surgical access and minimal haemodynamic instability.
Study NCT01930760 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Medical Training Educational
Description: Educational is modeled on the Theory of Planned Action, which proposes that unless people believe that their actions can have an effect on the desired outcome they have little incentive to act or persevere in the face of difficulties. Based on this theory we will be providing physicians with information on how to calculate, plot and track BMI and how this can be associated with identification of overweight children before they present with symptoms of obesity. This intervention will attempt to demonstrate that BMI calculating, plotting and tracking are useful diagnostic monitoring tools and that their actions may lead to more effective prevention and/or treatment.~The education intervention will not prescribe specific discussion initiation tools, although the participants will not be prevented from independently changing their communication behaviour.
Study NCT01930760 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing behavioural
Description: The behavioural intervention will incorporate specific Motivational Interviewing (MI) tools and information from a previously completed qualitative study with obese children (Obadia et al.). This study generated suggestions of how physicians can encourage children to think positively about making changes towards a healthier body weight. This intervention is designed to address physicians' lack of self-efficacy in communicating with children and their families about achieving a healthy body weight, and therefore would likely benefit from the input from children and the patient-centred theme of MI. It is based on the Trans-Theoretical Model and Stages of Change which postulates that people follow a step-wise progression towards change with specific constructs that need to be addressed before moving to the next step. These constructs are integral to the principles of MI
Study NCT04761744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Study treatment consists of nivolumab 3mg/kg, and will be repeated every 2 weeks.
Study NCT02795312 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Program
Description: Participants will take part in a 9-week Smoking Cessation Program
Study NCT04539860 — intervention group
Intervention type: DEVICE
Intervention: Transdermal Optical Imaging
Description: Blood pressure measurements completed by standard assessment methods and Transdermal Optical Imaging
Study NCT05757921 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perisolv (A)
Description: Intended for cleaning periodontal pockets for both periodontitis and peri-implantitis. Softens degenerative tissue and biofilm before depuration of periodontal pockets. Does not affect healthy tissue.
Study NCT05757921 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard (B)
Description: Deepened periodontal pockets to be treated are performed by subgingivally debridement. This is performed with piezoelectric ultrasound (EMS) under rinsing water and subgingival debridement with hand instrument.
Study NCT04124614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Up to 3 mg pill
Study NCT04124614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Up to 150 mg pill
Study NCT04124614 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Pill
Study NCT04124614 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pill
Study NCT03296631 — intervention group
Intervention type: OTHER
Intervention: collection of diapers with fresh stools
Description: collection of diapers with fresh stools
Study NCT01166061 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solution resembling active solution but without peptides
Study NCT01166061 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ToleroMune Grass
Description: 1 x4 administrations 4 weeks apart
Study NCT05840692 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram 20 mg
Description: Antidepressant
Study NCT05840692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT01591863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fidaxomicin
Description: 6 months-5 years 11 months: oral suspension, 32 mg/kg/day with a maximum dose of 400 mg/day, divided into two doses, every 12 hours for 10 days.~6 years-17 years 11 months: tablets, 200 mg every 12 hours for 10 days.
Study NCT00699218 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Stimulator Rapid2 made by Magstim Company Ltd. U.K.
Description: High frequency repetitive TMS given daily on weekdays for 3 weeks
Study NCT00848341 — intervention group
Intervention type: DEVICE
Intervention: GUIDANT ICD SYSTEM
Study NCT01479946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Electrochemotherapy
Description: bleomycin together with electroporation
Study NCT01495520 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Description: os, pill, 750 mg, b.i.d., 30 days
Study NCT01495520 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: os, pill, b.i.d., 30 days
Study NCT00424190 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Vancomycin plus IV Aztreonam
Description: vancomycin at 1 g parenteral infused over 60 minutes followed by aztreonam 1 g infused over 60 minutes, every 12 hours, for 5 to 14 days.
Study NCT00424190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftaroline
Description: 600 mg parenteral infused over 60 minutes, every 12 hours for 5 to 14 days
Study NCT02492256 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation
Description: CARTO- reconstruction LA, preferably during same rhythm as SUMO map (generally sinus rhythm) for use during registration of SUMO map in CARTO. Conventional PVI by circumferential antral ablation according to standard procedures. Exit and Entrance block conformation. Attempt to induce sustained atrial tachycardia. Optional mapping and ablation of post-ablation atrial tachycardia.
Study NCT02492256 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GP ablation guided by SUMO technology
Description: CARTO- reconstruction LA, preferably during same rhythm as SUMO map (generally sinus rhythm) for use during registration of SUMO map in CARTO. High frequency stimulation (HFS; 20-Hz frequency, 5-ms pulse duration, and 15-mA output) to access positive vagal response (the heart rate decreasing by 50% at baseline). RF Ablation of SUMO hotspots (in sinus rhythm if AF converts)~• Target a region of 1.0-1.5 cm diameter around the SUMO 'hotspot'. Control HFS. Attempt to induce sustained atrial tachycardia. Optional mapping and ablation of post-ablation atrial tachycardia.
Study NCT02492256 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ILR implantation
Description: Implantation the ECG loop recorder according to standard procedure
Study NCT02492256 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ILR implantation
Description: Implantation the ECG loop recorder according to standard procedure
Study NCT00668590 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient video decision aid & telephone coaching
Description: The decision aid is a 30 minute video program that educates patients about their role in diabetes care. Telephone coaching will assist patients in initiating behavior change.
Study NCT00668590 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Printed educational brochure
Description: The printed brochure is an educational brochure developed by the NIH.
Study NCT03396055 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: specific rehabilitation exercise
Description: specific rehabilitation exercise for patients with cervical myelopathy
Study NCT04319744 — intervention group
Intervention type: OTHER
Intervention: other
Description: Our hypothesis is that playing video games may have positive effects on videostile use, but there is no research on this subject Our goal is to compare the performances of anesthesia assistants who have played video games with those who did not.
Study NCT04316156 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Uincare Homeplus
Description: Interactive digital healthcare system
Study NCT04316156 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brochure
Description: Brochure
Study NCT02495688 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regional anesthesia
Description: Standard supraclavicular brachial plexus nerve block. Ultrasound-assisted. By an anesthesiologist. A mix of short- and medium lasting local anesthetics will be used.
Study NCT02495688 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: Standard procedure.
Study NCT01195688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 638683 or placebo
Description: oral doses given to 6 subjects per dose group